AP2A2

Across TCGA pan-cancer cohorts, AP2A2 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated AP2A2 data layer compared with 21 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher AP2A2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated AP2A2 expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

STAD, BLCA, and UCEC are the cancer types where AP2A2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Median	II,III,IV	0.122	0.663	<.001	30	view →
BLCA	DFS	Median	All	0.015	0.594	<.001	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
COAD	DFS	Median	All	0.224	0.696	.011	6	view →
LIHC	OS	Median	II,III,IV	0.239	0.715	.035	3	view →
SKCM	OS	Median	III,IV	0.819	0.378	.044	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

AP2A2–STAD (OS)

Open the STAD breakdown →